Cortexyme (NASDAQ:CRTX) & Genocea Biosciences (NASDAQ:GNCAQ) Critical Survey
Cortexyme (NASDAQ:CRTX) & Genocea Biosciences (NASDAQ:GNCAQ) Critical Survey
Cortexyme (NASDAQ:CRTX – Get Rating) and Genocea Biosciences (NASDAQ:GNCAQ – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, risk and profitability.
Cortexyme(納斯達克：CRTX-GET評級)和Genocea Biosciences(納斯達克：GNCAQ-GET評級)都是小盤醫療公司，但哪一家是優勢業務？我們將根據這兩家公司的股息實力、機構所有權、估值、收益、分析師建議、風險和盈利能力對它們進行比較。
Earnings & Valuation
收益與估值
This table compares Cortexyme and Genocea Biosciences' gross revenue, earnings per share and valuation.
下表比較了Cortex yme和Genocea Biosciences的毛收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cortexyme | N/A | N/A | -$89.94 million | ($2.97) | -0.31 |
| Genocea Biosciences | $1.64 million | 0.01 | -$33.20 million | ($0.61) | 0.00 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 皮質酶 | 不適用 | 不適用 | -8,994萬元 | ($2.97) | -0.31 |
| Genocea生物科學 | 164萬美元 | 0.01 | -3320萬美元 | ($0.61) | 0.00 |
Genocea Biosciences has higher revenue and earnings than Cortexyme. Cortexyme is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.
Genocea Biosciences的收入和收益比Cortexyme更高。Cortexyme的市盈率低於Genocea Biosciences，這表明它目前是兩隻股票中更負擔得起的一隻。
Analyst Ratings
分析師評級
This is a summary of recent recommendations for Cortexyme and Genocea Biosciences, as provided by MarketBeat.
這是由MarketBeat提供的Cortex yme和Genocea Bioscience的最新建議摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cortexyme | 0 | 0 | 1 | 0 | 3.00 |
| Genocea Biosciences | 0 | 0 | 0 | 0 | N/A |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 皮質酶 | 0 | 0 | 1 | 0 | 3.00 |
| Genocea生物科學 | 0 | 0 | 0 | 0 | 不適用 |
Cortexyme presently has a consensus target price of $15.00, suggesting a potential upside of 1,517.08%. Given Cortexyme's higher probable upside, equities analysts plainly believe Cortexyme is more favorable than Genocea Biosciences.
Cortexyme目前的共識目標價為15.00美元，暗示潛在上行1,517.08%。考慮到Cortexyme更有可能上行，股票分析師顯然認為Cortexyme比Genocea Biosciences更有利。
Insider and Institutional Ownership
內部人與機構持股
63.2% of Cortexyme shares are owned by institutional investors. Comparatively, 0.6% of Genocea Biosciences shares are owned by institutional investors. 27.9% of Cortexyme shares are owned by insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Cortexyme 63.2%的股份由機構投資者持有。相比之下，Genocea Biosciences 0.6%的股份由機構投資者持有。Cortexyme 27.9%的股份由內部人士持有。相比之下，Genocea Biosciences 1.6%的股份由內部人士持有。強大的機構持股表明，捐贈基金、對衝基金和大型基金管理公司相信，一家公司有望實現長期增長。
Profitability
盈利能力
This table compares Cortexyme and Genocea Biosciences' net margins, return on equity and return on assets.
此表比較了Cortex yme和Genocea Biosciences的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Cortexyme | N/A | -70.96% | -63.53% |
| Genocea Biosciences | N/A | N/A | N/A |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 皮質酶 | 不適用 | -70.96% | -63.53% |
| Genocea生物科學 | 不適用 | 不適用 | 不適用 |
Volatility and Risk
波動性和風險
Cortexyme has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 1.99, meaning that its share price is 99% more volatile than the S&P 500.
Cortex yme的貝塔係數為1.4，這意味着其股價的波動性比標準普爾500指數高出40%。相比之下，Genocea Biosciences的貝塔係數為1.99，這意味着其股價的波動性比標準普爾500指數高99%。
Summary
摘要
Genocea Biosciences beats Cortexyme on 6 of the 10 factors compared between the two stocks.
Genocea Biosciences在兩隻股票之間的10個因素中有6個擊敗了Cortexyme。
About Cortexyme
關於Cortex yme
(Get Rating)
(獲取評級)
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Cortexyme，Inc.是一家臨牀階段的生物製藥公司，專注於開發阿爾茨海默氏症和其他退行性疾病的療法。它的主要候選藥物是ATuzaginstat(COR388)，這是一種口服的腦穿透性小分子牙齦痛抑制劑，正處於II/III期臨牀試驗，用於輕至中度阿爾茨海默病患者，以及用於治療口腔鱗狀細胞癌、牙周炎和冠狀病毒感染。該公司成立於2012年，總部位於加利福尼亞州舊金山南部。
About Genocea Biosciences
關於Genocea生物科學
(Get Rating)
(獲取評級)
Genocea Biosciences, Inc. engages in the development and commercialization of cancer immunotherapies. The firm uses its proprietary technology platform, ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-011, an investigational adoptive T cell therapy and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.
Genocea生物科學公司致力於癌症免疫療法的開發和商業化。該公司使用其專有技術平臺ATLAS，根據實際的人類免疫反應識別臨牀相關的T細胞抗原。它的候選產品包括研究採用T細胞療法的Gen-011和新抗原癌症疫苗Gen-009。該公司由Robert Paull和Kevin J.Bitterman於2006年8月16日創立，總部設在馬薩諸塞州劍橋市。
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
接受Cortexyme Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊，接收對Cortexyme和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。